Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jeffrey R. Haworth"'
Autor:
David G. Alleva, Eline A. Feitsma, Yester F. Janssen, Hendrikus H. Boersma, Thomas M. Lancaster, Thillainaygam Sathiyaseelan, Sylaja Murikipudi, Andrea R. Delpero, Melanie M. Scully, Ramya Ragupathy, Sravya Kotha, Jeffrey R. Haworth, Nishit J. Shah, Vidhya Rao, Shashikant Nagre, Shannon E. Ronca, Freedom M. Green, Stephen A. Shaw, Ari Aminetzah, Schelto Kruijff, Maarten Brom, Gooitzen M. van Dam, Todd C. Zion
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-12 (2024)
Abstract AKS-452, a subunit vaccine comprising an Fc fusion of the ancestral wild-type (WT) SARS-CoV-2 virus spike protein receptor binding domain (SP/RBD), was evaluated without adjuvant in a single cohort, non-randomized, open-labelled phase II stu
Externí odkaz:
https://doaj.org/article/3e169ceb8cc4445682f02ab1847c3f9e
Autor:
Andrea R Delpero, Larry Karnes, Shannon E. Ronca, Shashikant Nagre, David G. Alleva, Sarah S Webb, Hanne Andersen Elyard, Allison I Jasa, Thomas M. Lancaster, JoAnn Yee, Sylaja Murikipudi, Vidhya Rao, Frans Sollie, Nishit J Shah, Freedom M Green, Melanie M Scully, Jeffrey R Haworth, Thillainaygam Sathiyaseelan, Emma K Greaves, Ramya Ragupathy, Jeffrey Klein, Todd C. Zion
Publikováno v:
Vaccine
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutra
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
Autor:
Yester F. Janssen, Eline A. Feitsma, Hendrikus H. Boersma, David G. Alleva, Thomas M. Lancaster, Thillainaygam Sathiyaseelan, Sylaja Murikipudi, Andrea R. Delpero, Melanie M. Scully, Ramya Ragupathy, Sravya Kotha, Jeffrey R. Haworth, Nishit J. Shah, Vidhya Rao, Shashikant Nagre, Shannon E. Ronca, Freedom M. Green, Ari Aminetzah, Frans Sollie, Schelto Kruijff, Maarten Brom, Gooitzen M. van Dam, Todd C. Zion
Publikováno v:
Vaccine
Vaccine, 40(9), 1253-1260. ELSEVIER SCI LTD
Vaccine, 40(9), 1253-1260. ELSEVIER SCI LTD
To address the coronavirus disease 2019 (COVID-19) pandemic caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recombinant subunit vaccine, AKS-452, is being developed comprising an Fc fusion protein of the SARS-